GENMAB A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,860.00 DKK | -0.27% |
|
-0.72% | -13.69% |
| 09-04 | Transcript : Genmab A/S Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 01:05 PM | |
| 09-04 | Morgan Stanley Upgrades Genmab to Equalweight, Price Target is $31 | MT |
Sales 2023 by Business Segment
Sales 2023 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Biotechnology | 5.37B | 10.11B | 8.48B | 14.6B | 16.47B | |||||
Total Assets | 15.14B | 21.14B | 24.63B | 30.28B | 35.29B | |||||
Interest Expense | -7M | -10M | -13M | -21M | -27M | |||||
Income Tax Expense | 693M | 1.15B | 975M | 1.51B | 1.28B | |||||
CAPEX | -111M | -307M | -252M | -317M | -366M | |||||
EBT | 2.86B | 5.9B | 3.98B | 7.04B | 5.64B | |||||
D&A | 187M | 266M | 304M | 398M | 240M | |||||
Operating Income | 2.64B | 6.31B | 3.02B | 6.36B | 5.32B | |||||
Net Income | 2.17B | 4.76B | 3.01B | 5.52B | 4.35B |
Geographical Revenue Distribution History
| Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
Denmark | 5.37B | 10.11B | 8.48B | 14.6B | 16.05B | |||||
Total Assets | 387M | 344M | 269M | 211M | 496M | |||||
United States of America | - | - | - | - | 380M | |||||
Total Assets | 68M | 370M | 470M | 442M | 378M | |||||
Japan | - | - | - | - | 41M | |||||
Total Assets | - | - | 95M | 70M | 56M | |||||
Netherlands | - | - | - | - | - | |||||
Total Assets | 252M | 380M | 422M | 793M | 874M |
- Stock Market
- Equities
- GMAB Stock
- Financials Genmab A/S
- Business Segments
MarketScreener is also available in this country: United States.
Switch edition